Post hoc THOR analysis links durable tumor response to erdafitinib with longer survival
Retrospective · BJU Int · 2026-11-10. Number 3 in the UrologyWatch Top 5 for November 10, 2026.
A post hoc analysis of the THOR trial found that among erdafitinib-treated patients with FGFR-altered metastatic urothelial carcinoma, those with durable objective response had substantially longer 6-month landmark overall survival than those with non-durable response (HR 8.71).
Why it matters: Suggests response durability, not just objective response rate, may better capture clinical benefit with erdafitinib, though this is a non-prespecified secondary analysis.
Limitation: Post hoc, non-prespecified exploratory analysis of trial data; results are hypothesis-generating rather than confirmatory.
Source: BJU Int · PubMed 43001410 · DOI 10.1111/bju.70533
Loading today's edition…